Teacher Retirement System of Texas Acquires 2,034 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Teacher Retirement System of Texas lifted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 17.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,708 shares of the company’s stock after purchasing an additional 2,034 shares during the quarter. Teacher Retirement System of Texas’ holdings in Pacira BioSciences were worth $258,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Caitlin John LLC raised its stake in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares during the last quarter. Virtus Investment Advisers Inc. bought a new position in shares of Pacira BioSciences in the 3rd quarter valued at about $98,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Stock Down 3.1 %

PCRX opened at $24.07 on Wednesday. The stock has a fifty day moving average of $24.84 and a 200-day moving average of $20.17. The company has a market capitalization of $1.11 billion, a P/E ratio of -11.86 and a beta of 0.86. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PCRX. HC Wainwright lifted their price target on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Needham & Company LLC lifted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.